Overview

Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1

Status:
NOT_YET_RECRUITING
Trial end date:
2029-09-23
Target enrollment:
Participant gender:
Summary
FCN-159 (Luvometinib Tablets), an orally available and highly potent selective inhibitor of MEK1/2,demonstrated good tolerability and exhibited notable anti-tumor activity in pediatric pts with NF1-related PN in study NCT04954001.This study is a 5-year long-term follow-up of the FCN-159-002 study, involving all enrolled patients to further assess safety, growth and development effects, and treatment efficacy.
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.